Q2 25 EPS
$4.42
BEAT +7.92%
Est. $4.10
Q2 25 Revenue
$75.45B
MISS 0.46%
Est. $75.80B
vs S&P Since Q2 25
-37.3%
TRAILING MARKET
COR -6.6% vs S&P +30.7%
Market Reaction
Did COR Beat Earnings? Q2 2025 Results
Cencora posted a solid fiscal second quarter, beating profit expectations comfortably while falling just short on the top line, as surging demand for specialty pharmaceuticals and GLP-1 products continued to power the business forward. Adjusted dilut… Read more Cencora posted a solid fiscal second quarter, beating profit expectations comfortably while falling just short on the top line, as surging demand for specialty pharmaceuticals and GLP-1 products continued to power the business forward. Adjusted diluted EPS came in at $4.42, beating the $4.10 consensus estimate by 7.92% and rising 16.3% from the prior year, while revenue climbed 10.3% year-over-year to $75.45 billion, a fraction below the $75.80 billion analysts had expected. The U.S. Healthcare Solutions segment was the clear engine of growth, expanding 11.4% on the strength of specialty drug volumes, while the International segment offered little help, with operating income slipping 17.3% to $159.30 million amid weakness in global specialty logistics. The January acquisition of Retina Consultants of America, financed with roughly $3.30 billion in new debt, added meaningful gross profit contribution even as it had limited near-term revenue impact due to intercompany eliminations. Encouraged by U.S. Earnings momentum, Cencora raised its full-year adjusted diluted EPS guidance to $15.70 to $15.95, up from $15.30 to $15.60 previously.
Key Takeaways
- • Unit volume growth in overall pharmaceutical distribution market
- • Increased sales of GLP-1 class products labeled for diabetes and/or weight loss
- • Specialty product sales to physician practices and health systems
- • January 2025 acquisition of Retina Consultants of America contributing to gross profit expansion
- • Share repurchases reducing diluted shares outstanding by 3.0%
- • Antitrust litigation settlement gains of $198.6 million
COR YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
COR Revenue by Segment
With YoY comparisons, source: SEC Filings
“Cencora's second quarter results reflect the strength of our value proposition as a healthcare services provider and the important role we play in the supply chain, driven by our pharmaceutical distribution footprint and complementary end-to-end services and solutions. We continue to advance our core business and enhance our capabilities, with a focus on elevating our solutions in the markets we serve.”
— Robert P. Mauch, Q2 2025 Earnings Press Release
COR Earnings Trends
COR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
COR EPS Trend
Earnings per share: estimate vs actual
COR Revenue Trend
Quarterly revenue: estimate vs actual
COR Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $4.73 | $4.75 | +0.48% | $78.36B | -3.31% |
| Q1 26 BEAT | $4.04 | $4.08 | +0.99% | $85.93B | -0.28% |
| Q4 25 BEAT FY | $3.79 | $3.84 | +1.44% | $83.73B | +0.40% |
| FY Full Year | $15.94 | $16.00 | +0.36% | $321.33B | +0.11% |
| Q3 25 BEAT | $3.84 | $4.00 | +4.23% | $80.66B | +0.68% |
| Q2 25 BEAT | $4.10 | $4.42 | +7.92% | $75.45B | -0.46% |